VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN. Int. J. Pharm. Sci. Drug Res. [Internet]. 2017 Sep. 1 [cited 2025 Oct. 24];9(5):224-7. Available from: https://ijpsdronline.com/index.php/journal/article/view/562